Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility

Table 2 Serious and non-serious adverse events (N = 9)

^*Serious adverse events included death, severe cardiopulmonary collapse, thrombosis of a major vessel, and unexpected events that were likely related to the study treatment. DIC: disseminated intravascular coagulation; PPHN: persistent pulmonary hypertension of the newborn

ISSN: 1471-2431